Risk factors

Monarch Casino & Resort faces significant concentration risk around its Atlantis property in Reno and Monarch Black Hawk in Colorado. Litigation and liens with the Monarch Black Hawk general contractor pose active operational and financial risks. Heavy dependence on key executives John and Bob Farahi and sensitivity to local discretionary spending and gaming taxes dominate.

Mosaic faces intense commodity price volatility and seasonal demand swings for its phosphate and potash crop nutrients. Operations carry heavy environmental and regulatory risks tied to water management, mining waste, and hazardous materials. Geopolitical and trade policies, including Canadian potash tariffs, directly threaten supply chains and costs.

Tenant distress, especially Steward’s operational and liquidity problems, dominates MPT’s risks and has already produced major impairment charges.

Risk section is dominated by separation liabilities from the spin-off with Voyix, heavy debt leverage, and ATM industry shifts.

Neumora faces substantial clinical and regulatory risks as a clinical-stage biopharmaceutical company focused on the historically challenging neuroscience field.

This company has no prior year filing. The risk section is dominated by market cycles, interest rate exposure, and key personnel dependencies.

Ocular Therapeutix faces significant ongoing losses, net losses of $193.5 million for 2024, and $891.1 million in accumulated deficit.

Onterris relies heavily on environmental services and emergency response contracts across volatile end markets like oil and gas.

Historical operating losses and significant reliance on cash reserves of $445.6 million dominate our financial risk profile.

Customer concentration and failure to meet contractual milestones or service levels threaten profitability and reputation.

Progyny operates in a highly competitive fertility benefits market dominated by its Smart Cycle model and Progyny Rx solution. Growth depends on retaining tech industry clients, expanding the Center of Excellence network, and managing pharmacy distribution partnerships. The business faces intense regulatory scrutiny regarding reproductive rights, healthcare laws, and state tax nexus rules.

Clinical stage biopharmaceutical company focused on discovering and developing treatments for fibrotic diseases, primarily dependent on lead candidate bexotegrast.